US Patent Issued to WIGEN BIOMEDICINE TECHNOLOGY (SHANGHAI) on April 14 for "Substituted pyrazinecarboxamide compounds for treating diseases related to EGFR mutation" (Chinese Inventors)

ALEXANDRIA, Va., April 15 -- United States Patent no. 12,600,714, issued on April 14, was assigned to WIGEN BIOMEDICINE TECHNOLOGY (SHANGHAI) Co. LTD. (Shanghai).

"Substituted pyrazinecarboxamide compounds for treating diseases related to EGFR mutation" was invented by Yuli Xie (Shanghai), Yingming Wu (Shanghai), Houxing Fan (Shanghai) and Lihui Qian (Shanghai).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to a compound as represented by general formula (1), and a preparation method therefor, and the use of the compound as represented by general formula (1) and an isomer, a crystal form, a pharmaceutically acceptable salt, a hydrate or a solvate thereof as an EGFR inhibitor in t...